BackPDL Biopharma Overview

PDL Biopharma Intangible Assets

PDL Biopharma's intangible assets is $13M.

Get informed when a big investor buys or sells

+ Follow
Intangible Assets
$13.19M
96.35% YoYΔ $-348.11M vs prior year quarter

Peer trimmed avg / median

Loading

PDL Biopharma Intangible Assets History

Loading

PDL Biopharma vs. peers: Intangible Assets Comparison

Loading

PDL Biopharma Intangible Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

PDL Biopharma (PDLI) FAQ

As of the most recent data (September 2020), PDLI shows a intangible assets of $13M. That compares with $360M in the prior-year period — down 96.4% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, PDLI's intangible assets is now $13M (was $360M) — a 96.4% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether PDL Biopharma is outperforming or lagging.

Tracking PDLI's intangible assets over time shows whether PDL Biopharma is scaling, shrinking, or reshaping that part of the business. The current reading is $13M That compares with $360M in the prior-year period — down 96.4% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this intangible assets page, Stockcircle has PDL Biopharma's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect intangible assets (currently $13M) with ownership activity and broader fundamentals.

PDL Biopharma's intangible assets is $13M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.